Should You Buy Black Diamond Therapeutics Inc (BDTX) Today? Analysis, Price Targets, and 2026 Outlook.
Analysis Updated At
2026/01/28
Not a good buy right now for a beginner long-term investor who is impatient. BDTX is a small-cap clinical-stage biotech with no revenue, worsening losses, a technically bearish trend (long-term downtrend), and mixed-to-negative Street momentum after a recent downgrade and toxicity concerns around its lead program. I would wait rather than deploy a meaningful portion of a $50k–$100k portfolio at this level.
Technical Analysis
Price/Trend: Current price ~2.59 is below key longer-term averages with a bearish moving-average stack (SMA_200 > SMA_20 > SMA_5), signaling a prevailing downtrend.
Momentum: RSI(6) ~48 (neutral) shows no strong oversold bounce signal.
MACD: Histogram slightly positive (0.0213) but contracting, implying fading upside momentum rather than a decisive reversal.
Levels: Pivot ~2.602 (price is just below/around it). Near support: S1 ~2.422 then S2 ~2.311. Near resistance: R1 ~2.781 then R2 ~2.892. Overall, the setup looks like a weak trend with overhead resistance and only modest signs of stabilization.
Intellectia Proprietary Trading Signals
- [AI Stock Picker](module://ai_stock_pick): No signal on given stock today.
- [SwingMax](module://swingmax): No signal on given stock today.
Analyst Ratings and Price Target Trends
Recent trend: Ratings/targets have weakened versus late-2025 optimism. On 2025-11-17 Piper initiated Overweight with a $9 target; on 2025-12-03 Guggenheim downgraded to Neutral due to toxicity/durability concerns; on 2026-01-16 Piper reiterated Overweight but cut target to $8 from $9.
Wall Street pros: Potentially large upside if clinical data de-risks silevertinib and execution improves; very low market cap can amplify upside on good data.
Wall Street cons: Material clinical risk (toxicity/durability), execution risk into Phase 3, and weakening sentiment via downgrade/target cuts.
Wall Street analysts forecast BDTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BDTX is 9 USD with a low forecast of 8 USD and a high forecast of 10 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Wall Street analysts forecast BDTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BDTX is 9 USD with a low forecast of 8 USD and a high forecast of 10 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Current: 2.570
Current: 2.570
